Three new reimbursement guidelines

03 April 2018

The Danish Medicines Agency has issued three new guidelines on reimbursement (in Danish only):

 

Guideline on application for general reimbursement and general conditional reimbursement

The guideline has been updated to reflect current practice in the area. The guideline now also includes an elaboration of when it is relevant to apply and an encouragement to enclose indirect comparisons if there are no relevant directly comparable clinical studies.

Link to the Guideline on application for general reimbursement and general conditional reimbursement (Retsinformation.dk – in Danish only)

Guideline on periodic reassessment of the reimbursement status of medicines

The new guideline replaces two guidelines in the area. The guideline has been updated to reflect current practice in the area while now also describing new abridged procedures for reassessment in cases where changes in reimbursement status have no adverse effects on the companies.

Link to the Guideline on periodic reassessment of the reimbursement status of medicines (Retsinformation.dk – in Danish only)

Guideline on the making of health economic analyses of medicines

The guideline is an update to the old guidelines for making health economic analyses of medicines from 1998. The guideline has been written with assistance from:

  • Professor, cand.oecon,  PhD, Dorte Gyrd-Hansen
  • Professor, cand.scient, MSc Health Econ, Jakob Kjellberg
  • Professor, cand.oecon, Kjeld Møller Pedersen
  • Professor, cand.oecon, PhD, Lars Holger Ehlers

The new guideline reflects sound health economic practice – at the national and international levels.

Link to the Guideline on the making of health economic analyses of medicines (Retsinformation.dk – in Danish only)

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.